Prior to joining Rezolute in 2017 as a founding member of the management team, Dr. Roberts directed clinical development at Fibrogen, Inc., where he helped successfully launch and execute the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease, concluding the largest Phase 3 program ever conducted in CKD anemia, and resulting in global NDA filings and approvals. During Dr. Roberts’ tenure, Fibrogen achieved the largest biotech IPO in the previous 10 years.

From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Cymabay, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, NASH, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy, as well as the successful filing of a NDA for Seladelpar.

He is an inventor or author on more than 25 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his M.D. Magna Cum Laude from Georgetown University. He completed a residency in Internal Medicine and a fellowship in Endocrinology at Stanford University Medical Center, where he also now serves as an Adjunct Associate Professor in the Division of Endocrinology.